Evidence map›Paper›PMID 37122549›Full record

ArticleRSC medicinal chemistry2023

Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action.

Fatma A M Mohamed, Saleha Y M Alakilli, Eman Fawzy El Azab, Faris A M Baawad, Esraa Ibrahim A Shaaban, Heba Abu Alrub, Omnia Hendawy, Hesham A M Gomaa, Adel G Bakr, Mostafa H Abdelrahman and 3 more

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Fatma A M MohamedDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences at Al-Qurayyat, Jouf University Al-Qurayyat 77454 Saudi Arabia fatmaahmed@ju.edu.sa.
Saleha Y M AlakilliDepartment of Biological Sciences, Faculty of Sciences, King Abdulaziz University Jeddah 23761 Saudi Arabia.
Eman Fawzy El AzabDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences at Al-Qurayyat, Jouf University Al-Qurayyat 77454 Saudi Arabia fatmaahmed@ju.edu.sa.
Faris A M BaawadM.B.B.S, Faculty of Medicine, King Abdulaziz University Jeddah 23761 Saudi Arabia.
Esraa Ibrahim A ShaabanDepartment of Biochemistry, Graduate; School of Medical Sciences, Nagoya City University Mizuho-cho, Mizuho-ku Nagoya 467-8601 Japan.
Heba Abu AlrubDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences at Al-Qurayyat, Jouf University Al-Qurayyat 77454 Saudi Arabia fatmaahmed@ju.edu.sa.
Omnia HendawyDepartment of Pharmacology, College of Pharmacy, Jouf University Sakaka 72341 Aljouf Saudi Arabia.
Hesham A M GomaaDepartment of Pharmacology, College of Pharmacy, Jouf University Sakaka 72341 Aljouf Saudi Arabia.ORCID https://orcid.org/0000-0001-7510-8428
Adel G BakrDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University Assiut Branch Assiut 71524 Egypt.
Mostafa H AbdelrahmanDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University Assiut 71524 Egypt.
Laurent TrembleauSchool of Natural and Computing Sciences, University of Aberdeen Meston Building Aberdeen AB243UE UK.ORCID https://orcid.org/0000-0001-6376-9077
Anber F MohammedPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University Assiut 71526 Egypt bgyoussif2@gmail.com +201098294419.
Bahaa G M YoussifPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University Assiut 71526 Egypt bgyoussif2@gmail.com +201098294419.ORCID https://orcid.org/0000-0002-6834-6548
Al-Azhar University · EGAssiut University · EGKing Abdulaziz University · SAAlexandria University · EGBeni-Suef University · EGJouf University · SANagoya City University · JPUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new series of 5-substituted-3-ethylindole-2-carboxamides 5a-k and 6a-c was designed and synthesised in an attempt to develop a dual targeted antiproliferative agent. Various spectroscopic methods of analysis were used to confirm the structures of the new compounds. The antiproliferative effect of compounds 5a-k and 6a-c against four cancer cell lines was investigated. Compounds 5a-k and 6a-c had significant antiproliferative activity against the four cancer cell lines tested, with mean GI

Identifiers

PMID37122549
PMCPMC10131667
OpenAlexW4327651597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.